Featured Research

from universities, journals, and other organizations

"Super-Aspirin" Improves Survival Rate, Reduces Complications For Diabetics Undergoing Heart Procedures

Date:
December 22, 1999
Source:
American Heart Association
Summary:
In the first study of its kind, researchers report that giving diabetics with heart disease the so-called "super-aspirin" greatly reduces complications and death rates following a procedure called stenting, according to a report in Circulation: Journal of the American Heart Association.

DALLAS, Dec. 21 - In the first study of its kind, researchers report that giving diabetics with heart disease the so-called "super-aspirin" greatly reduces complications and death rates following a procedure called stenting, according to a report in today's Circulation: Journal of the American Heart Association.

A stent is a small metal cylinder placed permanently inside a heart artery that has been weakened or clogged with fatty deposits called plaque. Such arteries are frequently opened with balloon angioplasty, but stents are widely used in addition to angioplasty to help hold the vessel open and to prevent re-blockage.

The "super aspirin" drug called abciximab keeps platelets from clumping and forming blood clots that can obstruct blood flow and trigger a heart attack.

The multicenter study called EPISTENT (Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial) involved 491 diabetic patients who were divided into three groups. One group received both a stent and the super-aspirin therapy. A second group underwent balloon angioplasty and also received the drug. The third group had a stent implanted, but received no drug, only a placebo.

One of the most surprising findings was that the re-blockage rate was cut in half in the patients who received both the stent and the drug. Those patients had an 8.1 percent re-blockage rate in the six months following the procedure, which is about half that of the other two groups.

"The stent-abciximab combination brought the re-blockage rate in the diabetic heart patients to about the same levels as heart patients without diabetes. It's the first time this has been demonstrated," says Steven P. Marso, M.D., lead author of the study and a fellow at the MidAmerica Heart Institute of St. Luke's Hospital, Kansas City, Mo.

"Previous studies have shown that abciximab reduces the heart attack and death rate in a variety of heart patients following balloon angioplasty. However, this latest study is the first to demonstrate that the drug combined with stent implantation reduces re-blockage of arteries specifically in diabetics," says Marso.

Two thirds of people with diabetes have some form of heart or blood vessel disease. They also tend to experience re-blockage of heart arteries following balloon angioplasty more often than patients who don't have diabetes.

Heart patients with diabetes are also more likely to have a heart attack in the six to 18 months following angioplasty, and they have higher death rate following the procedure, Marso says.

"I feel we proved that stenting combined with abciximab offers huge benefits to heart patients with diabetes," says co-author Eric J. Topol, M.D., chairman of cardiology at the Cleveland Clinic Foundation, Cleveland, Ohio.

Patients who received the drug, regardless of whether they underwent angioplasty, or received a stent, had a lower rate of heart attack or death in the six months following the procedure when compared to the patients in the stent-placebo group. However, the lowest rate - 6.2 percent - was seen in the stent-abciximab group. The combined death or heart attack rate in the six months following the procedure was 7.8 percent in the angioplasty-abciximab group and 12.7 percent in the stent-placebo group.

The abciximab was delivered intravenously around the time of the procedure and then for 12 hours afterward.

Marso says fewer than 2 percent of the patients in the study had side effects from abciximab such as bleeding or a low platelet count.

In an accompanying editorial, Spencer B. King III, M.D., director of interventional cardiology at Emory University in Atlanta, says the study's findings, if corroborated, will have a significant impact on the medical care of diabetic patients.

Co-authors are A. Michael Lincoff, M.D.; Stephen G. Ellis, M.D.; Deepak L. Bhatt, M.D.; Jean-Francois Tanguay, M.D.; Neal S. Kleiman, M.D.; Talal Hammoud, M.D.; Joan E. Booth, R.N.; and Shelly K. Sapp, M.S. Co-author of the editorial is Ehtisham Mahmud, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. ""Super-Aspirin" Improves Survival Rate, Reduces Complications For Diabetics Undergoing Heart Procedures." ScienceDaily. ScienceDaily, 22 December 1999. <www.sciencedaily.com/releases/1999/12/991222075746.htm>.
American Heart Association. (1999, December 22). "Super-Aspirin" Improves Survival Rate, Reduces Complications For Diabetics Undergoing Heart Procedures. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1999/12/991222075746.htm
American Heart Association. ""Super-Aspirin" Improves Survival Rate, Reduces Complications For Diabetics Undergoing Heart Procedures." ScienceDaily. www.sciencedaily.com/releases/1999/12/991222075746.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins